CIBC Asset Management Inc decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,004 shares of the medical equipment provider’s stock after selling 1,782 shares during the period. CIBC Asset Management Inc’s holdings in Hologic were worth $1,210,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. Vanguard Group Inc raised its stake in Hologic by 1.1% during the third quarter. Vanguard Group Inc now owns 28,259,273 shares of the medical equipment provider’s stock valued at $1,158,065,000 after buying an additional 303,902 shares in the last quarter. Parnassus Investments CA raised its position in shares of Hologic by 0.6% during the 1st quarter. Parnassus Investments CA now owns 15,640,395 shares of the medical equipment provider’s stock worth $756,995,000 after purchasing an additional 100,833 shares during the period. Geode Capital Management LLC raised its position in shares of Hologic by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 3,805,329 shares of the medical equipment provider’s stock worth $156,146,000 after purchasing an additional 190,788 shares during the period. Northern Trust Corp raised its position in shares of Hologic by 1.0% during the 4th quarter. Northern Trust Corp now owns 3,206,982 shares of the medical equipment provider’s stock worth $131,807,000 after purchasing an additional 30,422 shares during the period. Finally, FMR LLC raised its position in shares of Hologic by 4.8% during the 4th quarter. FMR LLC now owns 2,554,691 shares of the medical equipment provider’s stock worth $104,998,000 after purchasing an additional 116,507 shares during the period. Institutional investors own 96.41% of the company’s stock.
In other Hologic news, insider Peter J. Valenti III sold 4,545 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $44.07, for a total transaction of $200,298.15. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Sally Crawford sold 12,306 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $47.61, for a total value of $585,888.66. Following the transaction, the director now owns 168,886 shares in the company, valued at $8,040,662.46. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by company insiders.
Shares of HOLX traded up $0.16 during mid-day trading on Friday, reaching $47.84. The company’s stock had a trading volume of 917,058 shares, compared to its average volume of 1,732,901. The firm has a market capitalization of $12.78 billion, a P/E ratio of 21.45, a PEG ratio of 2.22 and a beta of 0.69. Hologic, Inc. has a 1 year low of $37.47 and a 1 year high of $48.82. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 1.31.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, May 1st. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.01. Hologic had a positive return on equity of 26.73% and a negative net margin of 0.32%. The company had revenue of $818.40 million during the quarter, compared to analyst estimates of $806.99 million. During the same quarter in the prior year, the company earned $0.53 earnings per share. The company’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, analysts expect that Hologic, Inc. will post 2.42 earnings per share for the current fiscal year.
HOLX has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, April 10th. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a research note on Friday, June 7th. TheStreet lowered Hologic from a “b” rating to a “c+” rating in a research note on Wednesday, May 1st. ValuEngine lowered Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price target (up from $50.00) on shares of Hologic in a research note on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $45.02.
COPYRIGHT VIOLATION NOTICE: This report was published by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://sundanceherald.com/2019/06/14/hologic-inc-holx-holdings-trimmed-by-cibc-asset-management-inc.html.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Recommended Story: The limitations of an equal weight rating
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.